Each ApoB particle can penetrate arterial walls regardless of LDL size. Total particle count is the true atherogenic load — not cholesterol mass alone.
Pattern B (small, dense LDL) carries 3× greater cardiovascular risk. Standard LDL-C misses this entirely — request NMR lipoprotein testing to distinguish particle pattern.
Genetically inherited. Elevates clot formation risk independent of lifestyle. Often never tested in standard panels — test once, as it rarely changes over a lifetime.
Hyperinsulinemia precedes type 2 diabetes by 10–15 years. Elevated insulin drives endothelial dysfunction, vascular inflammation, and myocardial fatty acid dysregulation.
Calculated from fasting glucose × insulin ÷ 405. Above 2.0 indicates early insulin resistance. Above 3.0 correlates strongly with metabolic syndrome and cardiac events.
Standard "normal" is <5.7%. Optimal cardiac protection requires <5.4%. Each 1% increase above 5.0% correlates with measurable rise in cardiovascular event risk.
Elevated hs-CRP doubles cardiac event risk independent of cholesterol. Standard CRP tests are too insensitive — request the high-sensitivity cardiovascular variant specifically.
A ratio above 3.0 is a strong surrogate for insulin resistance and small, dense LDL dominance. Simple to calculate from a standard panel — yet rarely discussed at visits.
Central adiposity is more predictive of cardiovascular events than BMI. Visceral fat secretes pro-inflammatory adipokines that drive insulin resistance and atherosclerosis.
Fat infiltration into the myocardium impairs contractile function and conduction. Risk factors include metabolic syndrome, elevated TG/HDL, and visceral obesity.
| Biomarker (click to expand) | Standard Range | HMI Optimal | Gap Risk | Significance |
|---|---|---|---|---|
| ApoB ▶ | < 130 mg/dL | < 65 mg/dL | High | 2× more permissive gap |
The standard ApoB cutoff of 130 mg/dL allows a particle burden that can silently build arterial plaque for years. At Heart Metabolics, the 65 mg/dL threshold reflects data showing significant plaque regression begins below this level. Most cardiologists won't flag a value of 110 mg/dL — but that patient may still be at elevated risk. | ||||
| Fasting Insulin ▶ | < 25 uIU/mL | < 6 uIU/mL | Critical | ~4× higher threshold |
A fasting insulin of 20 uIU/mL is technically "normal" yet represents significant hyperinsulinemia. Chronically elevated insulin damages the endothelium, promotes triglyceride synthesis, and drives LDL particle density toward Pattern B — all years before a diabetes diagnosis appears on a chart. | ||||
| HbA1c ▶ | < 5.7% | < 5.4% | Moderate | Risk rises in "normal" band |
The 5.4–5.7% band is technically normal but clinically meaningful. Glycation of LDL particles increases in this range, making them more atherogenic and more resistant to receptor clearance. Targeting below 5.4% is a proactive cardiovascular intervention, not just glycemic management. | ||||
| hs-CRP ▶ | < 3.0 mg/L | < 1.0 mg/L | High | Active inflammation 1–3 mg/L |
Values between 1–3 mg/L represent a state of subclinical vascular inflammation that dramatically increases the risk of plaque rupture. The JUPITER trial demonstrated that statins reduce cardiac events even in low-LDL patients when hs-CRP was elevated above 2 mg/L — a finding that validates why this marker can't be ignored. | ||||
| TG/HDL Ratio ▶ | Not assessed | < 2.0 | Critical | Best free IR proxy |
This ratio costs nothing to calculate — the values are already in every standard lipid panel. A ratio above 3.0 predicts small, dense LDL pattern with ~80% accuracy, outperforming LDL-C alone as a cardiac risk predictor in multiple studies. Ask your physician to calculate it during your appointment. | ||||
| HOMA-IR ▶ | Not ordered | < 1.5 | Critical | IR goes undetected 10+ yrs |
Insulin resistance typically precedes a type 2 diabetes diagnosis by 10–15 years. HOMA-IR is the most accessible clinical tool for quantifying it, yet is almost never ordered in routine care. A score above 1.5 warrants lifestyle intervention. Above 2.5 warrants immediate metabolic-cardiac review. | ||||
| Lp(a) ▶ | Rarely tested | < 30 mg/dL | High | 20% of patients unaware |
Up to 1 in 5 patients has an elevated Lp(a) that goes entirely undetected throughout their lifetime. Lp(a) is an independent cardiovascular risk factor that cannot be meaningfully lowered through diet or exercise alone — making early detection critical for informing statin choice, aspirin use, and emerging RNA-based therapies. | ||||
